Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

NCT02899104 · clinicaltrials.gov ↗

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG: Xofigo (Radium-223 dichloride, BAY88-8223)

Sponsor

Bayer